Quintrio
Home

IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

Myriad Genetics Inc

MYGN

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Last trade $5.54
Day change -$0.035 (-0.63%)
Day range $5.42 – $5.75
Volume 480,584
Market cap $534M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$534.29M
Price / earnings
—
Price / book
1.99×
Price / sales
0.66×
EV / sales
0.68×
EV / EBITDA
-9.64×

Profitability

Earnings per share
-$1.35
Return on assets
-21.19%
Return on equity
-47.99%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.45×
Current ratio
1.98×
Quick ratio
1.77×
Cash ratio
0.78×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$24.6M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for MYGN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$202.7M$190.7M$200.4M$209.8M$205.7M$213.1M$195.9M$210.6M
Cost of revenue$65M$63.7M$62.8M$63M$61.9M$61.3M$61.7M$59.7M
Gross profit$137.7M$127M$137.6M$146.8M$143.8M$151.8M$134.2M$150.9M
Selling, general and administrative$151.1M$140.9M$135.8M$124.3M$138.9M$138.7M$135.7M$136M
Research and development$26.5M$25M$27.1M$25.5M$28.2M$25.6M$27.5M$32.2M
Total operating expenses$177.6M$165.9M$168.3M$152.5M$167.1M$481M$163.2M$189.9M
Operating income-$39.9M-$38.9M-$30.7M-$5.7M-$23.3M-$329.2M-$29M-$39M
Interest expense-$4.1M-$4.1M-$4.1M-$4.4M-$3.8M-$1.5M-$800K-$700K
Income before taxes-$43.6M-$42.6M-$34.1M-$8.9M-$26.2M-$330.6M-$29.4M-$39.1M
Income taxes$300K$600K$0-$1M$1.2M-$100K-$29.3M$3.4M
Net income-$43.9M-$43.2M-$34.1M-$7.9M-$27.4M-$330.5M-$100K-$42.5M
Net income attributable to common shareholders-$43.9M-$43.2M-$34.1M-$7.9M-$27.4M-$330.5M-$100K-$42.5M
EBITDA-$27.3M-$26.4M-$12.8M$9.6M-$10.7M$1.6M-$14.6M$18.8M
Basic earnings per share-$0.46-$0.46-$0.36-$0.08-$0.29-$3.57$0.00-$0.47
Diluted earnings per share-$0.46-$0.46-$0.36-$0.08-$0.29-$3.57$0.00-$0.47

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue Estimates

Myriad Genetics (MYGN) reported a quarterly loss of $0.11 per share, beating consensus estimates of $0.17 loss, representing a 35.29% earnings surprise. Revenue of $202.7 million exceeded estimates by 7.48%, though down slightly year-over-year. The stock has underperformed the S&P 500 by 12.4% this year. Despite mixed performance, the company maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends, with the Medical - Biomedical and Genetics industry ranking in the top 45% of sectors.

GlobeNewswire Inc.

Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments

The global paternity and relationship testing market is expanding beyond traditional paternity testing into broader applications including maternity, grandparent, sibling, and infidelity testing. The market is projected to grow from $1.08 billion in 2025 to $1.45 billion by 2030 at a CAGR of 6.1%. Growth is driven by increased direct-to-consumer genetic testing accessibility, cultural shifts in family definitions, and demand for legally recognized testing. However, the market faces challenges from increased competition, lower pricing, and regulatory complexity across jurisdictions.

GlobeNewswire Inc.

Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial

Myriad Genetics announced the promotion of Vishal Sikri to Executive Vice President - Commercial effective September 16, 2026, replacing departing Chief Commercial Officer Brian Donnelly. Sikri, who previously served as SVP of Product, brings molecular diagnostics and oncology expertise. The company reaffirmed its full-year 2026 financial guidance.

GlobeNewswire Inc.

MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire is investigating Myriad Genetics for potential securities violations following the company's disappointing Q2 2026 earnings report. Myriad reported revenue of $190.7 million, down 11% year-over-year and significantly below consensus estimates. The company slashed full-year 2026 revenue guidance from $860-$880 million to $770-$790 million and suspended EBITDA guidance, citing reimbursement pressure, collection issues, and weak prenatal performance. This represents a dramatic $90 million midpoint cut just three months after reiterating prior guidance in May 2026.

GlobeNewswire Inc.

MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Law firm Kirby McInerney LLP is investigating Myriad Genetics for potential securities fraud following the company's July 30, 2026 earnings report. Myriad reported an 11% year-over-year revenue decline to $190.7 million, reduced full-year guidance, and an $11 million revenue adjustment. Hereditary cancer testing revenue fell 13% despite volume growth, attributed to lower reimbursement and unfavorable estimate changes. Management acknowledged delayed engagement with payers regarding authorization and denial issues. The stock declined 47% to $2.86 on July 31, 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Mar 26, 20092-for-1forward split